Results 191 to 200 of about 424,390 (258)

Multi-Omics Identification of Biomarkers for High-Altitude Pulmonary Hypertension. [PDF]

J Cardiovasc Dev Dis
Chen Z, Pang L, Zheng Y, Xu L, Tang M, Zhao Z, Wang T, Li J, Zhou Y, Duo L, Zhu W, Luo Z, Li F, Zhu D.   +13 more
europepmc   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Arterial tortuosity syndrome presenting as severe precapillary pulmonary hypertension in adulthood. [PDF]

Int J Cardiol Congenit Heart Dis
Baltodano Dangla CR, Romero Ríos CK, Urbina Maliaños CJ, Canales Reyes MA, Larios Alemán B, Lacayo Molina AL.   +5 more
europepmc   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Heart-Lung Interactions in Pulmonary Hypertension due to Heart Failure With Preserved Ejection Fraction. [PDF]

Compr Physiol
Prabala P, Raza F, Chesler NC.
europepmc   +1 more source

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller, Tobias Harm, Manuel Sigle, Parwez Aidery, Klaus‐Peter Kreisselmeier, Livia Baas, Andreas Goldschmied, Meinrad Paul Gawaz, Karin Anne Lydia Müller   +8 more
wiley   +1 more source

Corrigendum to “Exercise ventilatory reserve predicts survival in adult congenital heart disease associated pulmonary arterial hypertension with Eisenmenger physiology” [Int J Cardiol Congenit Heart Dis, Volume 7, March 2022, 100331]

International Journal of Cardiology Congenital Heart Disease
Chinthaka B. Samaranayake, Ruth McNiven, Aleksander Kempny, Carl Harries, Laura C. Price, Michael Gatzoulis, Konstantinos Dimopoulos, Stephen J. Wort, Colm McCabe   +8 more
doaj   +1 more source

Risk factors for secondary pulmonary hypertension in patients with silicosis. [PDF]

BMC Pulm Med
Zhen Y, Zhang XF, Guo WF, Ye J, Qiu CQ, Wu J.   +5 more
europepmc   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Impact of pulmonary hypertension on mortality in progressive massive fibrosis. [PDF]

Sarcoidosis Vasc Diffuse Lung Dis
Özgün S, Sarı G, Koyuncu A, Ezber R, Arslan MA, Doğan FM, Koç Ş, Şimşek C.   +7 more
europepmc   +1 more source